The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.

ABSTRACT:

Background

Diffuse hemispheric glioma, histone 3 (H3) G34-mutant, has been newly defined in the 2021 World Health Organization (WHO) classification of central nervous system tumors. Here we sought to define the prognostic roles of clinical, neuroimaging, pathological, and molecular features of these tumors.

Methods

We retrospectively assembled a cohort of 114 patients (median age 22 years) with diffuse hemispheric glioma, H3 G34-mutant, central nervous system WHO grade 4, and profiled the imaging, histological, and molecular landscape of their tumors.

Results

Compared with glioblastoma, H3 G34-mutant diffuse hemispheric gliomas exhibited less avid contrast enhancement, necrosis, and edema on MRI. Comprehensive analyses of mutational and DNA copy number profiles reveal

SUBMITTER: Le Rhun E 

PROVIDER: S-EPMC12309718 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature